Recursion Pharmaceuticals, Inc. slid over 2% in premarket trading after soaring over 125% in 2 weeks.
The company got a $50 million investment from Nvidia through a private investment in public equity deal two weeks ago.
They are partnering on drug discovery, where Recursion will process its own biological and chemical dataset on Nvidia's computing software, aimed at coming up with better drug discovery and developing biomolecular generative artificial intelligence models.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments